| Literature DB >> 31133647 |
Zehra Irshad1, Mingzhan Xue1, Amal Ashour1,2, James R Larkin1,3, Paul J Thornalley1,4, Naila Rabbani5,6.
Abstract
Metabolic dysfunction of endothelial cells in hyperglycemia contributes to the development of vascular complications of diabetes where increased reactive glycating agent, methylglyoxal (MG), is involved. We assessed if increased MG glycation induced proteotoxic stress, identifying related metabolic drivers and protein targets. Human aortal endothelial cells (HAECs) were incubated in high glucose concentration (20 mM versus 5 mM control) in vitro for 3-6 days. Flux of glucose metabolism, MG formation and glycation and changes in cytosolic protein abundances, MG modification and proteotoxic responses were assessed. Similar studies were performed with human microvascular endothelial HMEC-1 cells where similar outcomes were observed. HAECs exposed to high glucose concentration showed increased cellular concentration of MG (2.27 ± 0.21 versus 1.28 ± 0.03 pmol/106 cells, P < 0.01) and formation of MG-modified proteins (24.0 ± 3.7 versus 14.1 ± 3.2 pmol/106 cells/day; P < 0.001). In proteomics analysis, high glucose concentration increased proteins of the heat shock response - indicating activation of the unfolded protein response (UPR) with downstream inflammatory and pro-thrombotic responses. Proteins susceptible to MG modification were enriched in protein folding, protein synthesis, serine/threonine kinase signalling, glycolysis and gluconeogenesis. MG was increased in high glucose by increased flux of MG formation linked to increased glucose metabolism mediated by proteolytic stabilisation and increase of hexokinase-2 (HK-2); later potentiated by proteolytic down regulation of glyoxalase 1 (Glo1) - the major enzyme of MG metabolism. Silencing of Glo1, selectively increasing MG, activated the UPR similarly. Silencing of HK-2 prevented increased glucose metabolism and MG formation. trans-Resveratrol and hesperetin combination (tRES-HESP) corrected increased MG and glucose metabolism by increasing expression of Glo1 and decreasing expression of HK-2. Increased MG glycation activates the UPR in endothelial cells and thereby may contribute to endothelial cell dysfunction in diabetic vascular disease where tRES-HESP may provide effective therapy.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31133647 PMCID: PMC6536510 DOI: 10.1038/s41598-019-44358-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Dicarbonyl stress and increased protein glycation in human aortal endothelial cells in high glucose concentration. (a) The glyoxalase system. (b) Glycation of arginine residue by MG to form the major quantitative AGE, hydroimidazolone MG-H1. Dicarbonyl stress in HAECs after incubation for 6 days: (c) cellular MG, (d) MG concentration in conditioned culture medium, (e) MG-H1 adduct residue content of cytosolic protein, and (f) flux of MG-H1 free adduct released into culture medium. (g) FL adduct residue content of cytosolic protein, and (h) flux of FL free adduct released into culture medium. Data are mean ± SD (n = 3); significance: *, ** and ***P < 0.05, P < 0.01 and P < 0.001 with respect to low glucose concentration control; unpaired t-test.
Figure 2Metabolic drivers of dicarbonyl stress imposed by high glucose concentration in human endothelial cells in high glucose concentration in vitro. INCREASED MG FORMATION. HAECs: (a) Flux of D-lactate formation. (b) Glucose consumption. (c) Net flux of L-lactate formation. HMEC-1 cells. (d) Flux of D-lactate formation. (e) Glucose consumption. (f) Net flux of L-lactate formation. DOWN REGULATION OF GLO1. HAECs: (g) Glo1 activity. (h) Glo1 protein by Western blotting. (i) Glo1 mRNA. HMEC-1 cells: (j) Glo1 activity – effect of 5 mM D-glucose (LG), 30 mM D-glucose (D-HG), 5 mM D-glucose + 25 mM L-glucose (L-HG), and 5 mM D-glucose + 25 mM mannitol (Man). Significance: P = 0.042; ANOVA. (k) Glo1 protein by Western blotting. (l) Glo1 mRNA. (m) Glo1 ubiquitination. (n) Time course of Glo1 activity decline. Significance: treatment, P = 0.017; treatment by time, P < 0.001; ANOVA repeated measures. (o,p) Glucose concentration-dependent response of decreased Glo1 activity and increased flux of D-lactate, respectively. Significance: P = 0.001 and P = 0.008, respectively; ANOVA. Cell incubations were for 6 days unless otherwise stated. Data are mean ± SD (n = 3 except for n = 4 in (h)). Significance: *, ** and ***P < 0.05, P < 0.01 and P < 0.001, respectively, with respect to low glucose concentration control; unpaired t-test (unless otherwise stated). For metabolic flux measurements, analytes were determined at baseline and day 6 with the mean rate of change deduced.
Pathways enrichment analysis of proteins in high glucose cultures.
| Process | Pathway | Abundance Mean ± SD | Count | Fold enrichment | Significance | FDR | Proteins (Uniprot ID) |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Glucose metabolism | Gluconeogenesis | 1.80 ± 0.54 | 8 | 8.8 | 1.1E-02 | 3.5E-02 | ALDOA, G3P, MDHM, TPIS, PGAM1, AATC, ALDOC, PGK1 |
| Glycolysis | 1.56 ± 0.28 | 11 | 12.1 | 4.8E-06 | 1.5E-05 | ALDOA, PFKAP, KPYM, G3P, TPIS, HXK2, PP2AB, PGAM1, PP2AA, ALDOC, PGK1 | |
| Cell responses to stress | Regulation of HSF1-mediated heat shock response | 1.36 ± 0.10 | 11 | 5.5 | 1.1E-02 | 3.5E-02 | HSP7C, NU214, HS71B, RBP2, NU133, HS71L, HS105, BAG5, GRP78, RFA1, HS71A, GRP75 |
| Cell cycle | Separation of Sister Chromatids | 1.36 ± 0.20 | 18 | 3.4 | 8.5E-03 | 2.6E-02 | PSMD2, NUDC, RAGP1, CLIP1, TBB4A, PSME3, PSD13, PP2AB, PSD12, PP2AA, TBB4B, PSMD3, RBP2, PSMD1, NU133, PRS6A, XPO1, PRS10 |
| Metabolism of RNA | AUF1 (hnRNP D0) binds and destabilizes mRNA | 1.34 ± 0.15 | 11 | 6.9 | 1.5E-03 | 4.5E-03 | HSP7C, PSMD2, PSMD3, HS71B, PSME3, PSMD1, PRS6A, PSD13, PSD12, HS71A, HSPB1, PRS10 |
| Metabolism of amino acids | SeMet incorporation into proteins | 1.27 ± 0.10 | 9 | 28.8 | 2.6E-08 | 8.1E-08 | SYRC, SYEP, SYMC, SYK, MCA3, AIMP1, SYLC, SYQ, SYDC |
| Protein synthesis | Cytosolic tRNA aminoacylation | 1.27 ± 0.10 | 12 | 17.6 | 6.4E-09 | 2.0E-08 | SYRC, SYEP, SYMC, SYK, SYHC, MCA3, AIMP1, SYCC, SYLC, SYQ, IPYR, SYDC |
|
| |||||||
| Protein synthesis | L13a-mediated translational control | 0.76 ± 0.08 | 6 | 16.3 | 3.1E-03 | 2.7E-02 | RL5, RS2, RS20, RL35, RL13A, IF4E |
Other proteins INCREASED in high glucose concentration (Protein, increase, function): PAI-1, +118%, fibrinolysis inhibitor; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD), forms 1, 2 and 3, +52, +30% & +41%, post-translational processing of collagen; dihydropyrimidinase like 2, +38%, unknown function in ECs; fructose-2,6-bisphosphatase (TIGAR), +35%, increase of glycolysis; rho-associated protein kinase-1 (ROCK1), +20%, mitochondrial fission; ATG7, +19%, autophagy; BH3 interacting-domain death agonist (BID), +18, apoptosis. For pathways enrichment analysis, the significance given is with Bonferroni correction applied. All pathways with Bonferroni significance and FDR < 0.05 are shown, rank ordered by abundance increase (high to low).
Figure 3Activation of the unfolded protein response by dicarbonyl stress in human aortic endothelial cells in high glucose concentration. (a) Western blotting of heat shock protein response in HAECs incubated in 5 mM D-glucose (LG) and 20 mM D-glucose (HG) or 3 and 6 days. Western blot quantitation: (b) HSP70 (treatment, P = 0.012; ANOVA repeated measures); and (c) GRP78 (time, P = 0.015, treatment × time, P = 0.032; ANOVA repeated measures). (d) Western blotting of heat shock protein response in HAECs with siRNA knockdown of Glo1 incubated for 3 days under LG and HG conditions. Western blot quantitation: (e) Glo1 (P = 5 × 10−7; ANOVA), (f) HSP70 (P = 2 × 10−6; ANOVA) and (g) GRP78 (P = 3 × 10−5; ANOVA). Immunoblotting quantitation data are mean ± SD (n = 3). Key: empty bars, 5 mM D-glucose (LG); and filled bars, 20 mM D-glucose (HG). Significance: (b,d) *, ** and ***P < 0.5, P < 0.01 and P < 0.001 with respect to LG control, o, P < 0.05 with respect to 3 day HG control; (e) ***P < 0.001 with respect to scrambled siRNA transfected control (f,g) ** and ***P < 0.01 and P < 0.001 with respect to LG control, oo, P < 0.01 with respect to LG control; unpaired t-test (unless otherwise stated).
Figure 4Mass spectrometric detection of methylglyoxal-modified proteins and prediction of functional impact by RBD analysis. (a) MG-modified peptide identification. Pyruvate kinase-M, R120. Peptide fragmentation ion mass scan of peptide 116–125 with MG-H modification on R120 (+54.01): GPEIRMG-H1TGLIK; with fragment ion assignment table. Ions detected are color coded in the mass spectrum assignments with color shading in the table. m/z ion values unshaded were not detected and blank spaces in the table indicate ions are not expected chemically. Unique peptide with: peptide identity probability 0.997, mascot ion score 39.7, observed mass (m/z) 569.33 (2+), actual peptide mass 1136.645 amu, calculated +1H peptide mass 1137.663 amu. “Parent mass error” indicates error on the peptide mass r. (b) RBD plot for human pyruvate kinase-M2. Line-linked filled circles represent the primary sequence. The RBD is the area bound by the trapezium in the upper left-side region of the chart. Key: circle with red fill, MG-H1 residue in the RBD; circles with blue fill, unmodified arginine residues in the RBD; circles with yellow fill, other amino acid residues in the RBD; and circles with grey fill, amino acid residues outside the RBD.
Domain enrichment analysis of cytosolic proteins susceptible to glycation by methylglyoxal.
| Process | Protein domain | Count | Fold enrichment |
|---|---|---|---|
| Protein folding | Chaperonin TCP-1, conserved site | 7 | 68.1 |
| TCP-1-like chaperonin intermediate domain | 7 | 51.1 | |
| GroEL-like equatorial domain | 7 | 40.9 | |
| Chaperonin Cpn60/TCP-1 | 7 | 38.3 | |
| GroEL-like apical domain | 7 | 38.3 | |
| Signal transduction | 14-3-3 domain | 5 | 62.5 |
| Proteolysis | Proteasome, subunit alpha/beta | 8 | 36.9 |
| Protein synthesis | Aminoacyl-tRNA synthetase, class II | 6 | 30.9 |
| Actin cytoskeleton | Actin/actin-like conserved site | 7 | 29.2 |
| Actin, conserved site | 6 | 29.2 | |
| Actinin-type, actin-binding, conserved site | 6 | 22.8 | |
| Actin-related protein | 7 | 18.0 | |
| Protein synthesis | Aminoacyl-tRNA synthetase, class I, conserved site | 5 | 29.2 |
| Nucleotide binding | Rossmann-like alpha/beta/alpha sandwich fold | 7 | 14.6 |
Significant: P < 0.05 after Bonferroni correction and FDR < 0.05.
Figure 5Increased hexokinase-2 drives increased glucose metabolism in human aortic endothelial cells in high glucose concentration. (a) HK-1 and HK-2 protein abundance by proteomics (normalised to 5 mM glucose control). (b) Western blotting of HK-2 protein. (c) Densitometry quantitation of HK-2 protein (time, P = 0.041, treatment, P = 0.003, time × treatment, P = 0.003; ANOVA repeated measures). (d) HK-1 and HK-2 mRNA at 0.5, 1, 3 and 6 days - columns from left to right (normalised to 5 mM glucose control). (e) HAEC glycogen content. Cell incubations were for 6 days unless otherwise stated. HK-2 gene silencing study: (f) Western blotting of HK-2 protein and densitometry quantitation of HK-2 protein, P < 0.001, ANOVA; (g) effect on glucose consumption, P < 0.001, ANOVA; and (h) effect on D-lactate formation, P = 0.003, ANOVA. Cell incubations were for 3 days. Data are mean ± SD (n = 3). Significance: *, ** and ***P < 0.05, P < 0.01 and P < 0.001 with respect to low glucose concentration control and o, oo and ooo, P < 0.05, P < 0.01 and P < 0.001 with respect to high glucose concentration control; unpaired t-test (unless otherwise stated).
Figure 6Reversal of metabolic dysfunction in human aortic endothelial cells in high glucose concentration by trans-resveratrol-hesperetin combination. Metabolic measurements. (a) Glo1 activity (P = 7 × 10−11, ANOVA). (b) Flux of D-lactate formation (P = 7 × 10−11, ANOVA). (c) Glucose consumption (P = 8 × 10−9, ANOVA). (d) Concentration of IL-8 in conditioned medium (P = 2 × 10−5, ANOVA). Western blotting. (e) G6PD protein (P = 1 × 10−8, ANOVA). (f) HK-2 protein (P = 4 × 10−5, ANOVA). Key: hollow bars and “LG”, incubations with 5 mM D-glucose; filled bars and “HG”, incubations with 20 mM D-glucose; and “tRES-HESP”, incubations with 10 μM tRES-HESP. Data are mean ± SD (n = 4 for (a); for (c–f) n = 3 except n = 8 for LG and HG controls in (b,c). Significance: *, ** and ***P < 0.05, P < 0.01 and P < 0.001 with respect to LG control; oo and ooo, P < 0.01 and P < 0.001 with respect to HG control (unpaired t-test).
Figure 7Schematic diagram of the mechanisms of activation of the unfolded protein responsive and pro-inflammatory response by dicarbonyl stress and increased glucose metabolism in endothelial cells in hyperglycemia. (a) Activation of the cytosolic and endoplasmic reticulum UPR by misfolded MG-modified proteins. (b) Increased glucose metabolism, mitochondrial dysfunction and glycogen synthesis by stabilisation of HK-2 to proteolysis by cytosolic hyperglycemia. Abbreviations: PKC, protein kinase C; VDAC, voltage-dependent anion channel.